US · PULM · BIOTECHNOLOGY
Pulmatrix, Inc. (PULM) intrinsic value and stock valuation
$1.27as of 2026-11-21 · Mkt cap 6.06M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Pulmatrix, Inc. DCF and intrinsic value
InvestorsCraft values PULM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PULM’s statements →
Pulmatrix, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $7.81M | $7.3M | $6.07M | $5.17M |
| Operating income | -$-5.17M | -$-9.76M | -$-14.74M | -$-18.95M | -$-20.17M |
| Net income | -$-5.16M | -$-9.56M | -$-14.12M | -$-18.84M | -$-20.17M |
| EPSd | -$-1.41M | -$-2.62M | -$-3.87M | -$-5.46M | -$-7.44M |
| Operating cash flow | -$-5.43M | -$-10.72M | -$-15.98M | -$-19.36M | -$-19.73M |
| Capital expenditure | $0.00 | -$-400K | -$-680K | -$-90K | -$-140K |
| Free cash flow | -$-5.43M | -$-11.11M | -$-16.66M | -$-19.44M | -$-19.87M |
| Total assets | $4.14M | $9.94M | $34M | $41M | $58.8M |
| Total debt | $0.00 | $0.00 | $8.76M | $860K | $2.29M |
| Net debt | -$-4.09M | -$-9.52M | -$-10.42M | -$-34.77M | -$-51.55M |
| Total equity | $3.81M | $8.95M | $18M | $31.1M | $47.5M |
| Cash and short-term investments | $4.09M | $9.52M | $19.2M | $35.6M | $53.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $7.81M | $7.3M | $6.07M | $5.17M |
| Cost of revenue | $40K | $7.17M | $15.5M | $18.2M | $15.4M |
| Gross profit | -$-40K | $640K | -$-8.22M | -$-12.17M | -$-10.21M |
| Research and development expenses | $40K | $7.17M | $15.5M | $18.2M | $15.4M |
| Selling, general and administrative expenses | $5.13M | $7.79M | $6.52M | $6.78M | $6.38M |
| Other expenses | -$-40K | -$-4.55M | -$-15.52M | -$-18.24M | -$-11.8M |
| Operating expenses | $5.13M | $10.4M | $6.52M | $6.78M | $9.95M |
| Cost and expenses | $5.17M | $17.6M | $22M | $25M | $25.3M |
| Interest income | $140K | $470K | $870K | $310K | $10K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $0.00 | $110K | $130K | $160K | $170K |
| Ebitda | -$-5.16M | -$-7.04M | -$-13.99M | -$-18.67M | -$-16.42M |
| Operating income | -$-5.17M | -$-9.76M | -$-14.74M | -$-18.95M | -$-20.17M |
| Total other income/expenses, net | $10K | $200K | $620K | $110K | -$0.00 |
| Income before tax | -$-5.16M | -$-9.56M | -$-14.12M | -$-18.84M | -$-20.17M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-5.16M | -$-9.56M | -$-14.12M | -$-18.84M | -$-20.17M |
| Weighted average shares outstanding | $3.65M | $3.65M | $3.65M | $3.45M | $2.34M |
| Weighted average diluted shares outstanding | $3.65M | $3.65M | $3.65M | $3.45M | $2.71M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.09M | $9.52M | $19.2M | $35.6M | $53.8M |
| Net receivables | $0.00 | $0.00 | $930K | $1.3M | $70K |
| Inventory | $0.00 | $0.00 | $0.00 | $150K | $0.00 |
| Total current assets | $4.13M | $9.92M | $20.8M | $38.2M | $54.8M |
| Property, plant and equipment, net | $0.00 | $0.00 | $11.5M | $940K | $2.41M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $10K | $10K | $1.47M | $1.47M | $1.62M |
| Total non-current assets | $10K | $20K | $13.1M | $2.81M | $4.04M |
| Total assets | $4.14M | $9.94M | $34M | $41M | $58.8M |
| Accounts payable | $270K | $810K | $1.92M | $1.19M | $840K |
| Short-term debt | $0.00 | $0.00 | $430K | $860K | $1.43M |
| Deferred revenue | $0.00 | $0.00 | $620K | $1.34M | $940K |
| Total current liabilities | $330K | $930K | $3.91M | $5.02M | $4.44M |
| Long-term debt | $0.00 | $0.00 | $8.33M | $0.00 | $860K |
| Deferred revenue, non-current | $0.00 | $0.00 | $3.73M | $4.82M | $6.07M |
| Total non-current liabilities | $0.00 | $70K | $12.1M | $4.82M | $6.93M |
| Capital lease obligations | $0.00 | $0.00 | $8.76M | $860K | $2.29M |
| Total liabilities | $330K | $1M | $16M | $9.84M | $11.4M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-302.32M | -$-297.16M | -$-287.6M | -$-273.48M | -$-254.64M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $3.81M | $8.95M | $18M | $31.1M | $47.5M |
| Total investments | $10K | $10K | $1.47M | $1.47M | $1.62M |
| Total debt | $0.00 | $0.00 | $8.76M | $860K | $2.29M |
| Net debt | -$-4.09M | -$-9.52M | -$-10.42M | -$-34.77M | -$-51.55M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-5.16M | -$-9.56M | -$-14.12M | -$-18.84M | -$-20.17M |
| Depreciation and amortization | $0.00 | $430K | $1.48M | $1.54M | $1.24M |
| Stock-based compensation | $30K | $510K | $950K | $1.11M | $1.16M |
| Change in working capital | -$-230K | -$-4.79M | -$-4.3M | -$-3.18M | -$-5.53M |
| Accounts receivable | $0.00 | $930K | $370K | -$-1.23M | $20K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-2.07M |
| Accounts payable | -$-540K | -$-1.11M | $730K | $510K | -$-150K |
| Net cash provided by operating activities | -$-5.43M | -$-10.72M | -$-15.98M | -$-19.36M | -$-19.73M |
| Investments in property, plant and equipment | $0.00 | -$-400K | -$-680K | -$-90K | -$-140K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | -$-400K | -$-680K | -$-90K | -$-140K |
| Common stock issued | $0.00 | $0.00 | $50K | $1.38M | $37.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | -$-3.2M |
| Net cash used for financing activities | $0.00 | $0.00 | $50K | $1.23M | $43.5M |
| Net change in cash | -$-5.43M | -$-11.11M | -$-16.61M | -$-18.21M | $23.6M |
| Cash at end of period | $4.1M | $9.53M | $20.6M | $37.3M | $55.5M |
| Operating cash flow | -$-5.43M | -$-10.72M | -$-15.98M | -$-19.36M | -$-19.73M |
| Capital expenditure | $0.00 | -$-400K | -$-680K | -$-90K | -$-140K |
| Free cash flow | -$-5.43M | -$-11.11M | -$-16.66M | -$-19.44M | -$-19.87M |
Line items
Line items
Line items
About Pulmatrix, Inc.
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
- CEO
- Peter Ludlum
- Employees
- 2
- Beta
- 1.90
Explore
Frequently asked questions
What is the intrinsic value of Pulmatrix, Inc. (PULM)?
InvestorsCraft does not currently publish an intrinsic value for PULM. How the IC value is calculated.
Is PULM undervalued?
InvestorsCraft does not publish an undervaluation signal for PULM at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.